Skip to content
Gatifloxacin
Zymaxid (gatifloxacin) is a small molecule pharmaceutical. Gatifloxacin was first approved as Zymar on 2003-03-28. It is used to treat bacterial conjunctivitis, bacterial infections, bacterial pneumonia, bronchitis, and cystitis amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
eye diseasesD005128
urogenital diseasesD000091642
Trade Name
FDA
EMA
Zymaxid (generic drugs available since 2013-08-28, discontinued: Zymar)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gatifloxacin
Tradename
Company
Number
Date
Products
ZYMAXIDAbbVieN-022548 RX2010-05-18
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
gatifloxacinNDA authorized generic2016-09-01
zymaxidNew Drug Application2016-09-05
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial conjunctivitisEFO_1000829D003234H10.0
bacterial infectionsD001424A49
bacterial pneumoniaEFO_1001272D018410J15.9
bronchitisD001991J40
cystitisEFO_1000025D003556N30
escherichia coli infectionsEFO_1001318D004927B96.20
gonorrheaDOID_7551D006069A54
haemophilus infectionsEFO_1001127D006192
klebsiella infectionsEFO_1001353D007710
proteus infectionsEFO_1001130D011512
Show 7 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
J01: Antibacterials for systemic use
J01M: Quinolone antibacterials
J01MA: Fluoroquinolone antibacterials, systemic
J01MA16: Gatifloxacin
S: Sensory organ drugs
S01: Ophthalmologicals
S01A: Antiinfective ophthalmologics
S01AE: Fluoroquinolone antiinfectives, ophthalmologic
S01AE06: Gatifloxacin
HCPCS
No data
Clinical
Clinical Trials
3 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pathologic processesD01033511
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Brain diseasesD001927HP_0001298G93.4011
Spinal cord diseasesD013118HP_0002196G95.911
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324I25.111
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGATIFLOXACIN
INNgatifloxacin
Description
Gatifloxacin is a monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes. It has a role as an antiinfective agent, an EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor and an antimicrobial agent. It is a quinolinemonocarboxylic acid, a N-arylpiperazine, an organofluorine compound, a quinolone and a quinolone antibiotic.
Classification
Small molecule
Drug classantibacterials (quinolone derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
Identifiers
PDB
CAS-ID112811-59-3
RxCUI1546025
ChEMBL IDCHEMBL31
ChEBI ID5280
PubChem CID5379
DrugBankDB01044
UNII ID81485Y3A9A (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,007 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,024 adverse events reported
View more details